Skip to main content
SpringerLink
Log in

Polymer-Drug Conjugates

  • Chapter
  • First Online:
Fundamentals of Pharmaceutical Nanoscience

  • 2979 Accesses

Abstract

Polymer-drug conjugates are nanosized drug delivery systems, which comprise several drug molecules covalently attached to a polymeric carrier. This chapter provides an overview of this technology in the context of drug delivery. Particular emphasis is given to different approaches and techniques used to synthesise and characterise polymer-drug conjugates. In the final part of the chapter current applications of this technology are also discussed.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  • Albain KS, Belani CP, Bonomi P, O’Byrne KJ, Schiller JH, Socinski M (2006) PIONEER: a phase III randomized trial of paclitaxel poliglumex versus paclitaxel in chemotherapy-naïve women with advanced-stage non-small-cell lung cancer and performance status of 2. Clin Lung Cancer 7:417–419

    Article  PubMed  CAS  Google Scholar 

  • Ashwell G, Harford J (1982) Carbohydrate-specific receptors of the liver. Annu Rev Biochem 51:531–554

    Article  PubMed  CAS  Google Scholar 

  • Beeram M, Rowinsky EK, Hammond LA, Patnaik A, Schwartz GH, de Bono JS, Forero L, Forouzesh B, Berg KE, Rubin EH, Beers S, Killian A, Kwiatek J, McGuire J, Spivey L, Takimoto CH (2002) A phase I and pharmacokinetic (PK) study of PEG-paclitaxel in patients with advanced solid tumors. Proc Am Soc Clin Oncol 21:405

    Google Scholar 

  • Borad MJ, Hamm JT, Rosen LS, Jameson GS, Utz J, Mulay M, Eldon M, Dhar S, Acosta L, Von Hoff DD (2008) Phase I dose finding and pharmacokinetic study of NKTR-102 (PEGylated irinotecan): early evidence of anti-tumor activity. J Clin Oncol 26:13518

    Google Scholar 

  • Calvo E, Hoch U, Maslyar DJ, Tolcher AW (2010) Dose-escalation phase I study of NKTR-105, a novel pegylated form of docetaxel. J Clin Oncol 28:TPS160

    Article  Google Scholar 

  • Campone M, Rademaker-Lakhai JM, Bennouna J, Howell SB, Nowotnik DP, Beijnen JH, Schellens JHM (2007) Phase I and pharmacokinetic trial of AP5346, a DACH–platinum–polymer conjugate, administered weekly for three out of every 4 weeks to advanced solid tumor patients. Cancer Chemother Pharmacol 60:523–533

    Article  PubMed  CAS  Google Scholar 

  • Canal F, Sanchis J, Vicent MJ (2011) Polymer-drug conjugates as nano-sized medicines. Curr Opin Biotechnol 22:894–900

    Article  PubMed  CAS  Google Scholar 

  • Clementi C, Miller K, Mero A, Satchi-Fainaro R, Pasut G (2011) Dendritic poly(ethylene glycol) bearing paclitaxel and alendronate for targeting bone neoplasms. Mol Pharm 8:1063–1072

    Article  PubMed  CAS  Google Scholar 

  • Danhauser-Riedl S, Hausmann E, Schick HD, Bender R, Dietzfelbinger H, Rastetter J, Hanauske AR (1993) Phase I clinical and pharmacokinetic trial of dextran conjugated doxorubicin (AD-70, DOX-OXD). Invest New Drugs 11:187–195

    Article  PubMed  CAS  Google Scholar 

  • Daud A, Garrett C, Simon GR, Munster P, Sullivan D, Stromatt S, Allevi C, Bernareggi B (2006) Phase I trial of CT-2106 (polyglutamated camptothecin) administered weekly in patients with advanced solid tumors. In: ASCO annual meeting proceedings. J Clin Oncol 24:2015

    Google Scholar 

  • Duncan R (2006) Polymer conjugates as anticancer nanomedicines. Nat Rev Cancer 6:688–701

    Article  PubMed  CAS  Google Scholar 

  • Greco F, Vicent MJ, Gee S, Jones AT, Gee J, Nicholson RI, Duncan R (2007) Investigating the mechanism of enhanced cytotoxicity of HPMA copolymer–Dox–AGM in breast cancer cells. J Control Release 117:28–39

    Article  PubMed  CAS  Google Scholar 

  • Guo Z, Wheler JJ, Naing A, Mani S, Goel S, Mulcahy M, Gamza F, Longley C, Buchbinder A, Kurzrock R (2008) Clinical pharmacokinetics (PK) of EZN-2208, a novel anticancer agent, in patients (pts) with advanced malignancies: a phase I, first-in-human, dose-escalation study. J Clin Oncol 26:2556

    Google Scholar 

  • Hamm JT, Richards D, Ramanathan RK, Becerra C, Jameson G, Walling J, Gribben D, Dhar S, Eldon M, Von Hoff D (2009) Dose-finding study of NKTR-102 in combination with cetuximab. J Clin Oncol 27:13503

    Google Scholar 

  • Haunstetter A, Izumo S (1998) Apoptosis: basic mechanisms and implications for cardiovascular disease. Circ Res 82:1111–1129

    Article  PubMed  CAS  Google Scholar 

  • Homsi J, Simon GR, Garret CR, Springett G, De Conti R, Chiappori AA, Munster PN, Burton MK, Stromatt S, Allievi C, Angiuli P, Eisenfeld A, Sullivan DM, Daud AI (2007) Phase I trial of poly-L-glutamate camptothecin (CT-2106) administered weekly in patients with advanced solid malignancies. Clin Cancer Res 13:5855–5861

    Article  PubMed  CAS  Google Scholar 

  • Hwang J, Rodgers K, Oliver JC, Schluep T (2008) Alpha-methylprednisolone conjugated cyclodextrin polymer-based nanoparticles for rheumatoid arthritis therapy. Int J Nanomed 3:359–371

    CAS  Google Scholar 

  • Jensen BV (2006) Cardiotoxic consequences of anthracycline-containing therapy in patients with breast cancer. Semin Oncol 33:S15–S21

    Article  PubMed  CAS  Google Scholar 

  • Julyan PJ, Seymour LW, Ferry DR, Daryani S, Boivin CM, Doran J, David M, Anderson D, Christodoulou C, Young AM, Hesslewood S, Kerr DJ (1999) Preliminary clinical study of the distribution of HPMA copolymers bearing doxorubicin and galactosamine. J Control Release 22:281–290

    Article  Google Scholar 

  • Kostkova H, Etrych T, Rihova B, Ulbrich K (2011) Synergistic effect of HPMA copolymer-bound doxorubicin and dexamethasone in vivo on mouse lymphomas. J Bioactive Compatible Polym 26:270–286

    Article  CAS  Google Scholar 

  • Langer CJ, O’Byrne KJ, Socinski MA, Mikhailov SM, Lesniewski-Kmak K, Smakal M, Ciuleanu TE, Orlov SV, Dediu M, Heigener D, Eisenfeld AJ, Sandalic L, Oldham FB, Singer JW, Ross HJ (2008) Phase III trial comparing paclitaxel poliglumex (CT-2103, PPX) in combination with carboplatin versus standard paclitaxel and carboplatin in the treatment of PS 2 patients with chemotherapy-naıve advanced non-small cell lung cancer. J Thorac Oncol 3:623–630

    Article  PubMed  Google Scholar 

  • Li C, Yu DF, Newman RA, Cabrai F, Stephens LC, Hunter N, Milas L, Wallace S (1998) Complete regression of well-established tumors using a novel water-soluble poly(L-glutamic acid)-paclitaxel conjugate. Cancer Res 58:2404–2409

    PubMed  CAS  Google Scholar 

  • Liu XM, Quan LD, Tian J, Laquer FC, Ciborowski P, Wang D (2010) Synthesis of click PEG-dexamethasone conjugates for the treatment of rheumatoid arthritis. Biomacromolecules 11:2621–2628

    Article  PubMed  CAS  Google Scholar 

  • Maeda H, Nakamura H, Fang J (2013) The EPR effect for macromolecular drug delivery to solid tumours: improvement of tumour uptake, lowering of systemic toxicity, and distinct tumour imaging in vivo. Adv Drug Deliv Rev 65:71–79

    Article  PubMed  CAS  Google Scholar 

  • Malet G, Martín AG, Orzáez M, Vicent MJ, Masip I, Sanclimens G, Ferrer-Montiel A, Mingarro I, Messeguer A, Fearnhead HO, Pérez-Payá E (2006) Small molecule inhibitors of Apaf-1-related caspase-activation that control mitochondrial-dependent apoptosis. Cell Death Differ 13:1523–1532

    Article  PubMed  CAS  Google Scholar 

  • Matsumura Y, Maeda H (1986) A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumour agent SMANCS. Cancer Res 46:6387–6392

    PubMed  CAS  Google Scholar 

  • Mattson MP (2000) Apoptosis in neurodegenerative disorders. Nat Rev Mol Cell Biol 1:120–129

    Article  PubMed  CAS  Google Scholar 

  • Meerum Terwogt JM, ten Bokkel Huinink WW, Schellens JH, Schot M, Mandjes IA, Zurlo MG, Rocchetti M, Rosing H, Koopman FJ, Beijnen JH (2001) Phase I clinical and pharmacokinetic study of PNU166945, a novel water-soluble polymer-conjugated prodrug of paclitaxel. Anticancer Drug 12:315–323

    Article  CAS  Google Scholar 

  • Miller K, Eldar-Boock A, Polyak D, Segal E, Benayoun L, Shaked Y, Satchi-Fainaro R (2011) Antiangiogenic antitumor activity of HPMA copolymer-paclitaxel-alendronate conjugate on breast cancer bone metastasis mouse model. Mol Pharm 8:1052–1062

    Article  PubMed  CAS  Google Scholar 

  • Muzykantov VR, Torchilin VP (2003) Biomedical aspects of drug targeting. Springer, New York

    Google Scholar 

  • Nan A, Nanayakkara D, Larry A, Walker LA, Yardley V, Croft SL, Ghandehari H (2001) N-(2-hydroxypropyl)methacrylamide (HPMA) copolymers for targeted delivery of 8-aminoquinoline antileishmanial drugs. J Control Release 77:233–243

    Article  PubMed  CAS  Google Scholar 

  • Nan A, Croft SL, Yardley V, Ghandehari H (2004) Targetable watersoluble polymer-drug conjugates for the treatment of visceral leishmaniasis. J Control Release 94:115–127

    Article  PubMed  CAS  Google Scholar 

  • Neumann TA, Van Patischen H, Marcantonio A, Song D, Morrison P, Eldon MA (2007) Evaluation of single oral doses of NKTR118 (PEG-naloxol) as a peripheral opioid antagonist (POA): a double-blind placebo-controlled study in healthy male subjects. J Clin Pharmacol 47:1210

    Google Scholar 

  • O’Brien M, Oldham E (2005) Paclitaxel poliglumex vs. gemcitabine or vinorelbine for the treatment of performance status (PS) 2 patients with chemotherapy-naïve advanced non-small cell lung cancer (NSCLC): the STELLAR 4 phase III study. In: 2005 ASCO annual meeting, p 1122

    Google Scholar 

  • O’Brien M, Socinski MA, Popovich AY, Bondarenko IN, Tomova A, Bilynskyi BT, Hotko YS, Ganul VL, Kostinsky IY, Eisenfeld AJ, Sandalic L, Oldham FB, Bandstra B, Sandler AB, Singer JW (2008) Randomized phase III trial comparing single-agent paclitaxel poliglumex (CT-2103, PPX) with single-agent gemcitabine or vinorelbine for the treatment of PS 2 patients with chemotherapy-naive advanced non-small cell lung cancer. J Thorac Oncol 3:728–734

    Article  PubMed  Google Scholar 

  • Oliver JC, Yen Y, Synold TW, Schluep T, Davis M (2008) A dose-finding pharmacokinetic study of IT-101, the first de novo designed nanoparticle therapeutic in refractory solid tumors. J Clin Oncol 26:14538

    Google Scholar 

  • Paridaens R, Biganzoli L, Bruning P, Klijn JGM, Gamucci T, Houston S, Coleman R, Schachter J, Van Vreckem A, Sylvester R, Awada A, Wildiers J, Piccart M (2000) Paclitaxel versus doxorubicin as first-line single-agent chemotherapy for metastatic breast cancer: a European organization for research and treatment of cancer randomized study with cross-over. J Clin Oncol 18:724–733

    PubMed  CAS  Google Scholar 

  • Pasut G, Greco F, Mero A, Mendichi R, Fante C, Green RJ, Veronese FM (2009) Polymer-drug conjugates for combination anticancer therapy: investigating the mechanism of action. J Med Chem 52:6499–6502

    Article  PubMed  CAS  Google Scholar 

  • Paul A, Vicent MJ, Duncan R (2007) Using small-angle neutron scattering to study the solution conformation of N-(2-hydroxypropyl)methacrylamide copolymer-doxorubicin conjugates. Biomacromolecules 8:1573–1579

    Article  PubMed  CAS  Google Scholar 

  • Paz-Ares L, Ross H, O’Brien M, Riviere A, Gatzemeier U, Von Pawel J, Kaukel E, Freitag L, Digel W, Bischoff H, Garcìa-Campelo R, Iannotti N, Reiterer P, Bover I, Prendiville J, Eisenfeld AJ, Oldham FB, Bandstra B, Singer JW, Bonomi P (2008) Phase III trial comparing paclitaxel poliglumex vs docetaxel in the second-line treatment of non-small-cell lung cancer. Br J Cancer 98:1608–1613

    Article  PubMed  CAS  Google Scholar 

  • Pimm MV, Perkins AC, Duncan R, Ulbrich K (1993) Targeting of N-(2-hydroxypropyl) methacrylamide copolymer-doxorubicin conjugate to the hepatocyte galactose-receptor in mice: visualisation and quantification by gamma scintigraphy as a basis for clinical targeting studies. J Drug Target 1:125–131

    Article  PubMed  CAS  Google Scholar 

  • Pinciroli V, Rizzo V, Angelucci F, Tatò M, Vigevani A (1997) 1H NMR characterization of methacrylamide polymer conjugates with the anti-cancer drug doxorubicin. Magn Reson Chem 35:2–8

    Article  CAS  Google Scholar 

  • Rademaker-Lakhai JM, Terret C, Howell SB, Baud CM, de Boer RF, Pluim D, Beijnen JH, Schellens JHM, Droz JP (2004) A phase I and pharmacological study of the platinum polymer AP5280 given as an intravenous infusion once every 3 weeks in patients with solid tumors. Clin Cancer Res 10:3386–3395

    Article  PubMed  CAS  Google Scholar 

  • Ringsdorf H (1975) Structure and properties of pharmacologically active polymers. J Polym Sci 51:135–153

    CAS  Google Scholar 

  • Roy P, Das S, Auddy RG, Mukherjee A (2012) Biological targeting and drug delivery in control of Leishmaniasis. J Cell Anim Biol 6:73–87

    CAS  Google Scholar 

  • Santucci L, Mencarelli A, Renga B, Pasut G, Veronese F, Zacheo A, Germani A, Fiorucci S (2006) Nitric oxide modulates proapoptotic and antiapoptotic properties of chemotherapy agents: the case of NO-pegylated epirubicin. FASEB J 20:765–767

    PubMed  CAS  Google Scholar 

  • Satchi-Fainaro R, Puder M, Davies JW, Tran HT, Sampson DA, Greene AK, Corfas G, Folkman J (2004) Targeting angiogenesis with a conjugate of HPMA copolymer and TNP-470. Nat Med 10:255–261

    Article  PubMed  CAS  Google Scholar 

  • Satchi-Fainaro R, Mamluk R, Wang L, Short SM, Nagy JA, Feng D, Dvorak AM, Dvorak HF, Puder M, Mukhopadhyay D, Folkman J (2005) Inhibition of vessel permeability by TNP-470 and its polymer conjugate, caplostatin. Cancer Cell 7:251–261

    Article  PubMed  CAS  Google Scholar 

  • Sausville EA, Garbo LE, Weiss GJ, Shkolny D, Yurkovetskiy AV, Bethune C, Ramanathan RK, Fram RJ (2010) Phase I study of XMT-1001 given IV every 3 weeks to patients with advanced solid tumors. J Clin Oncol 28:13121

    Google Scholar 

  • Schoemaker NE, van Kesteren C, Rosing H, Jansen S, Swart M, Lieverst J, Fraier D, Breda M, Pellizzoni C, Spinelli R, Porro MG, Beijnen JH, Schellens JHM, Bokkel Huinink WW (2002) A phase I and pharmacokinetic study of MAG-CPT, a water-soluble polymer conjugate of camptothecin. Br J Cancer 87:608–614

    Article  PubMed  CAS  Google Scholar 

  • Scott LC, Yao JC, Benson AB, Thomas AL, Falk S, Mena RR, Picus J, Wright J, Mulcahy MF, Ajani JA, Evans TRJ (2009) A phase II study of pegylated-camptothecin (pegamotecan) in the treatment of locally advanced and metastatic gastric and gastro-oesophageal junction adenocarcinoma. Cancer Chemother Pharmacol 63:363–370

    Article  PubMed  CAS  Google Scholar 

  • Segal E, Pan H, Benayoun L, Kopečková P, Shaked Y, Kopeček J, Satchi-Fainaro R (2009) Enhanced anti-tumor activity and safety profile of targeted nano-scaled HPMA copolymer-alendronate-TNP-470 conjugate in the treatment of bone malignances. Biomaterials 32:4450–4463

    Article  Google Scholar 

  • Seymour LW, Ulbrich K, Wedge SR, Hume IC, Strohalm J, Duncan R (1991) N-(2-hydroxypropyl)methacrylamide copolymers targeted to the hepatocyte galactose-receptor: pharmacokinetics in DBA2 mice. Br J Cancer 63:859–866

    Article  PubMed  CAS  Google Scholar 

  • Seymour LW, Ferry DR, Anderson D, Hesslewood S, Julyan PJ, Poyner R, Doran J, Young AM, Burtles S, Kerr DJ (2002) Hepatic drug targeting: phase I evaluation of polymer-bound doxorubicin. J Clin Oncol 15:1668–1676

    Article  Google Scholar 

  • Seymour LW, Ferry DR, Kerr DJ, Rea D, Whitlock M, Poiner R, Boivin C, Hesslewood S, Twelves C, Blackie R, Schatzlein A, Jodrell D, Bissett D, Calvert H, Lind M, Robbins A, Burtles S, Duncan R, Cassidy J (2009) Phase II studies of polymer-doxorubicin (PK1, FCE28068) in the treatment of breast, lung and colorectal cancer. Int J Oncol 34:1629–1636

    Article  PubMed  CAS  Google Scholar 

  • Soepenberg O, de Jonge MJA, Sparreboom A, de Bruin P, Eskens FALM, de Heus G, Wanders J, Cheverton P, Ducharme MP, Verweij J (2005) Phase I and pharmacokinetic study of DE-310 in patients with advanced solid tumors. Clin Cancer Res 11:703–711

    Article  PubMed  CAS  Google Scholar 

  • Vasey PA, Kaye SB, Morrison R, Twelves C, Wilson P, Duncan R, Thomson AH, Murray LS, Hilditch TE, Murray T, Burtles S, Fraier D, Frigerio E, Cassidy J (1999) Phase I clinical and pharmacokinetic study of PK1 [N-(2-hydroxypropyl)methacrylamide copolymer doxorubicin]: first member of a new class of chemotherapeutic agents-drug-polymer conjugates. Clin Cancer Res 5:83–94

    PubMed  CAS  Google Scholar 

  • Vicent MJ, Perez-Paya E (2006) Poly-l-glutamic acid (PGA) aided inhibitors of apoptotic protease activating factor 1 (Apaf-1): an antiapoptotic polymeric nanomedicine. J Med Chem 49:3763–3765

    Article  PubMed  CAS  Google Scholar 

  • Vicent MJ, Greco F, Nicholson RI, Paul A, Griffiths PC, Duncan R (2005) Polymer therapeutics designed for a combination therapy of hormone-dependent cancer. Angew Chem Int Ed 44:4061–4066

    Article  CAS  Google Scholar 

  • Webster L, Dhar S (2009) NKTR-118 significantly reverses opioid-induced constipation poster. In: 20th AAPM annual clinical meeting

    Google Scholar 

  • Wu KJ, Odom RW (1998) Characterizing synthetic polymers by MALDI MS. Anal Chem News Features 1:456–461

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Reading School of Pharmacy, University of Reading, Whiteknights, UK

    Cristina Fante & Francesca Greco

Authors
  1. Cristina Fante
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Francesca Greco
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Francesca Greco .

Editor information

Editors and Affiliations

  1. UCL School of Pharmacy, University College London, London, United Kingdom

    Ijeoma F. Uchegbu

  2. UCL School of Pharmacy, University College London, London, United Kingdom

    Andreas G. Schätzlein

  3. Bexleyheath, United Kingdom

    Woei Ping Cheng

  4. School of Pharmacy & Biomedical Sciences, University of Portsmouth, Portsmouth, United Kingdom

    Aikaterini Lalatsa

Rights and permissions

Reprints and permissions

Copyright information

© 2013 Springer Science+Business Media New York

About this chapter

Cite this chapter

Fante, C., Greco, F. (2013). Polymer-Drug Conjugates. In: Uchegbu, I., Schätzlein, A., Cheng, W., Lalatsa, A. (eds) Fundamentals of Pharmaceutical Nanoscience. Springer, New York, NY. https://doi.org/10.1007/978-1-4614-9164-4_7

Download citation

Publish with us

Policies and ethics

Search

Navigation